Stock IGMS IGM BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
9.4 USD +22.88% Intraday chart for IGM Biosciences, Inc. +30.56% +13.12%
04-17 IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets MT
04-17 IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
IGM Biosciences to Reduce Workforce by 22%, Pause Hematologic Oncology Clinical Development
MORNING BRIEFING - USA/Asien
Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%
IGM Biosciences, Inc. Announces Plans to File IND for IGM-2644 (CD38 x CD3) to Treat Autoimmune Disease
IGM Biosciences Q3 Loss Narrows, Collaboration Revenue Rises; Shares Fall After Hours
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
IGM Biosciences, Inc. Announces Board Changes
IGM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
IGM Biosciences Plans $100 Million Public Stock Offering, Concurrent Private Placement of Securities; Shares Fall
IGM Biosciences, Inc. Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
IGM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
IGM Biosciences Q4 Net Loss Narrows
IGM Biosciences Says First Patient Dosed in Trial for Potential Solid Tumor Treatment
IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors
IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development
Insider Buy: Igm Biosciences
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGMS Stock
  4. News IGM Biosciences, Inc.
  5. Other languages